Angiodynamic Inc(ANGO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.89 | Insider Own | 11.54% | Shs Outstand | 41.7M | Perf Week | -1.29% |
| Market Cap | 0.63B | Forward P/E | - | EPS next Y | 83.08% | Insider Trans | -0.49% | Shs Float | 36.6M | Perf Month | -3.05% |
| Enterprise Value | 0.59B | PEG | - | EPS next Q | -0.11 | Inst Own | 96.78% | Short Float | 3.73% | Perf Quarter | 26.41% |
| Income | -0.04B | P/S | 1.97 | EPS this Y | -77.29% | Inst Trans | -2.13% | Short Ratio | 3.04 | Perf Half Y | 42.58% |
| Sales | 0.32B | P/B | 3.73 | EPS next 5Y | - | ROA | -13.43% | Short Interest | 1.36M | Perf YTD | 18.93% |
| Book/sh | 4.1 | P/C | 11.72 | EPS past 3/5Y | 12.67% -1.46% | ROE | -20.77% | 52W High | -6.26% ($16.29) | Perf Year | 39.32% |
| Cash/sh | 1.3 | P/FCF | - | Sales past 3/5Y | -1.86% 1.93% | ROIC | -20.4% | 52W Low | 62.62% ($9.39) | Perf 3Y | 111.5% |
| Dividend Est. | - | EV/EBITDA | 933.73 | EPS Y/Y TTM | -6.34% | Gross Margin | 51.29% | Volatility(W/M) | 3.34% 3.06% | Perf 5Y | -43.65% |
| Dividend TTM | - | EV/Sales | 1.84 | Sales Y/Y TTM | 9.46% | Oper. Margin | -6.97% | ATR (14) | 0.49 | Perf 10Y | -6.89% |
| Dividend Ex-Date | - | Quick Ratio | 1.48 | EPS Q/Q | -85.3% | Profit Margin | -11.48% | RSI (14) | 48.53 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.18 | Sales Q/Q | 8.05% | SMA20 | -2.54% ($15.67) | Beta | 0.31 | Target Price | $20 |
| Payout | - | Debt/Eq | 0.06 | Earnings | 2026/7/14 | SMA50 | 3.32% ($14.78) | Rel Volume | 0.76 | Prev Close | $15.24 |
| Employees | 632 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | 21.96% 7.93% | SMA200 | 24.15% ($12.3) | Avg Volume(3M) | 0.45M | Price | $15.27 |
| IPO | 2004/5/27 | Option/Short | Yes/Yes | Trades | 4965 | Volume | 341,959 | Change | 0.2% |
Company
ANGO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🩺 AngioDynamics (ANGO) is a US-based medical technology company specializing in the development of minimally invasive medical devices for the treatment of vascular disease and the removal of cancerous tumors. The company went public on the NASDAQ market in 2004 and provides precision treatment solutions to medical professionals worldwide in the areas of peripheral arterial occlusion treatment and tumor ablation surgery through its advanced technology platforms, NanoKnife and IsoLoc (Orion).
Over the past 1 year, on the higher side
6% below its 1-year high.
ANGO has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -77.3% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 2 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +111.5% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 96.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
XHE 0.01%
QQQS 0.00%
KOMP 0.00%
IWC 0.00%
SMLV 0.00%It ranks #4 in the industry
Based on market cap of $631M.
ANGO $631M PER -
ISRG $131B PER 42.4
BDX $48B PER 53.6
MDLN $43B PER 38.1
FAQ
What kind of company is ANGO?
ANGO belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of ANGO?
The market cap of ANGO is approximately $631M, ranking 3,026 within its sector.
What is the 52-week high and low for ANGO?
ANGO has recorded a 52-week high of $16.29 and a low of $9.39.
